Literature DB >> 10022999

Infrequent alteration of p53 pathway in metastatic renal cell carcinoma.

T Kawasaki1, V Bilim, K Takahashi, Y Tomita.   

Abstract

Renal-cell carcinoma (RCC) is known to be highly resistant to conventional chemotherapy and irradiation suggesting that RCC cells do not easily undergo apoptosis, though p53 mutation is an infrequent event in RCC. p53 is responsible for the expression of p21WAF1 and bax genes, and these expressions are involved in the G1 arrest or apoptosis when cells are exposed to genotoxic stimuli. These gene mutations have been detected and their dysfunction may lead to accumulation of genomic alterations. We investigated the p53, p21WAF1 and bax gene mutations in 5 patients who had primary RCC and metastatic tumors. In one case only the metastatic tumor had non-sense transversion in the p53 gene, whereas the primary tumor showed no p53 gene mutation. no p21WAF1 and bax mutations were detected in any primary RCC or metastatic tumors. These findings suggest that, in RCC, inactivation of p53 might contribute to progression of the disease but inactivation of p21WAF1 and bax are not likely to play significant roles in the defective p53 pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022999     DOI: 10.3892/or.6.2.329

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

2.  Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.

Authors:  Inga Peters; Natalia Dubrowinskaja; Hossein Tezval; Mario W Kramer; Christoph A von Klot; Jörg Hennenlotter; Arnulf Stenzl; Ralph Scherer; Markus A Kuczyk; Jürgen Serth
Journal:  Target Oncol       Date:  2014-09-19       Impact factor: 4.493

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

Review 4.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

5.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

6.  Immunohistochemistry of p53 and Ki-67 and p53 mutation analysis in renal epithelioid angiomyolipoma.

Authors:  Wenbin Li; Lei Guo; Xingang Bi; Jianhui Ma; Shan Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome.

Authors:  Alexander Laird; Fiach C O'Mahony; Jyoti Nanda; Antony C P Riddick; Marie O'Donnell; David J Harrison; Grant D Stewart
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.